NLRP3 and neoplasm: First, activation of TAMs releases IL‐1α and IL‐1β to act on tumour cells, activating the intracellular NF‐κB pathway, which next exerts a pro‐coagulant effect by affecting NLRP3 inflammatory vesicles.132